1. Home
  2. HTD vs CSTL Comparison

HTD vs CSTL Comparison

Compare HTD & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HTD

John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$25.80

Market Cap

916.6M

Sector

Finance

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$28.19

Market Cap

940.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTD
CSTL
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
916.6M
940.8M
IPO Year
2003
2019

Fundamental Metrics

Financial Performance
Metric
HTD
CSTL
Price
$25.80
$28.19
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$47.17
AVG Volume (30 Days)
68.6K
461.3K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
N/A
$2.10
Revenue Next Year
N/A
$12.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.66
52 Week Low
$20.31
$14.59
52 Week High
$26.12
$44.28

Technical Indicators

Market Signals
Indicator
HTD
CSTL
Relative Strength Index (RSI) 63.26 31.66
Support Level $24.30 $21.77
Resistance Level $25.72 $34.97
Average True Range (ATR) 0.34 1.76
MACD 0.01 -0.15
Stochastic Oscillator 63.51 16.22

Price Performance

Historical Comparison
HTD
CSTL

About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest

John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: